SenzaGen (SENZA.ST) Stock Analysis & AI Equity Report
SenzaGen (SENZA.ST) overview
SenzaGen (SENZA.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, SenzaGen reported revenue of SEK 58.0m and operating profit of SEK -11.5m; the year-end share price was 6.08 SEK and market capitalisation was SEK 179m. SenzaGen is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get SenzaGen's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-11. Data will be refreshed during report generation.
About SenzaGen
SenzaGen AB provides in vitro toxicity testing and advisory services focused on non-animal chemical safety assessment. Its GARD platform uses genomics and machine learning to test skin and respiratory sensitization, including quantitative potency assessment and methods for medical device materials. The company also offers biological evaluation and biocompatibility services through GLP-certified laboratories.
Generate the SenzaGen report
SenzaGen is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for SenzaGen and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.